Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid

Laurent Degos(Inserm), Sylvie Castaigné(Hôpital André Mignot), Pierre Fenaux(Saint Louis University Hospital), Christine Chomienne(Inserm), Hervé Dombret(University of London Institute in Paris), Roland Berger(Memorial Sloan Kettering Cancer Center), Marie Thérèse Daniel

The Lancet

December 1, 1990

10.1016/0140-6736(90)93135-c

Cited by 137

Related Papers

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

|Blood|2016|5.9k

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

|Blood|2009|3.4k

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

|Blood|2022|3.1k

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

|Blood|2022|2.8k

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

|The Lancet Oncology|2014|1.3k